Alberto Espay, MD, MSc, University of Cincinnati, Cincinnati, OH, explains the importance of biological subtyping for future successes in personalized treatments for neurodegenerative diseases. The current diagnosis of neurodegenerative diseases considers the symptoms of the disease but not the underlying biological processes. Understanding the biological cause of the disease will allow for treatment with therapies that target the specific process, meaning increased efficacy of treatments. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть